Delphine Giusti - JoVE Visualize

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

RMD Open|November 21, 2024

Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patientsKevin Didier, Vincent Sobanski, Ailsa Robbins, et al.

Frontiers in Immunology|December 31, 2020

Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS StudyNellie Bourse Chalvon, Pauline Orquevaux, Delphine Giusti, et al.

The British Journal of Dermatology|October 4, 2023

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patientsRéda Chebani, Florian Lombart, Guillaume Chaby, et al.

Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

RMD Open|November 21, 2024

Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patientsKevin Didier, Vincent Sobanski, Ailsa Robbins, et al.

Frontiers in Immunology|December 31, 2020

Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS StudyNellie Bourse Chalvon, Pauline Orquevaux, Delphine Giusti, et al.

The British Journal of Dermatology|October 4, 2023

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patientsRéda Chebani, Florian Lombart, Guillaume Chaby, et al.

Pageof 5